PCN54 COST-MINIMIZATION ANALYSIS OF FLUDARABINE ASSOCIATED TO ALEMTUZUMAB (FLUCAM) VERSUS THE ASSOCIATION OF FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) IN THE SECOND LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) UNDER THE BRAZ ...
May 1, 2009, 00:00
10.1016/S1098-3015(10)73291-5
https://www.valueinhealthjournal.com/article/S1098-3015(10)73291-5/fulltext
Title :
PCN54 COST-MINIMIZATION ANALYSIS OF FLUDARABINE ASSOCIATED TO ALEMTUZUMAB (FLUCAM) VERSUS THE ASSOCIATION OF FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) IN THE SECOND LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) UNDER THE BRAZ ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)73291-5&doi=10.1016/S1098-3015(10)73291-5
First page :
Section Title :
Open access? :
No
Section Order :
716